How Eltoukhy was paid
$8.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Helmy EltoukhyChairman and Co-Chief Executive Officer | $1 | — | $8,647,709 | — | — | $13,422 | $8,661,132 |
| AmirAli TalasazCo-Chief Executive Officer | $1 | — | $8,647,709 | — | — | $13,517 | $8,661,227 |
| Michael BellChief Financial Officer | $566,154 | — | $1,873,317 | $907,059 | $399,000 | $10,875 | $3,756,405 |
| Darya ChudovaChief Technology Officer | $520,192 | $10,000 | $1,756,012 | $824,606 | $367,500 | $10,729 | $3,489,039 |
| Craig EagleChief Medical Officer | $576,154 | $10,000 | $1,404,827 | $659,701 | $304,500 | $14,975 | $2,970,157 |
| John SaiaChief Legal Officer | $527,116 | $5,000 | $1,545,291 | $725,663 | $371,000 | $11,314 | $3,185,384 |
What changed and why
- $982.0MRevenue increased 33% to $982.0 million in 2025 driven by volume growth across oncology and screening portfolios.
- $1Co-CEOs received a base salary of $1 and target equity awards in lieu of cash compensation.
- 92.5%At the 2025 annual meeting, the say-on-pay proposal received 92.5% support from stockholders.
- $183.8MGross profit increased by $183.8 million to $633.0 million for the 2025 fiscal year.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.